Eli Lilly & Co. (LLY)
$35.20
0.42 (+1.21%)
| CAPS Rating |
|
|---|---|
| Open | $0.00 |
| Previous Close | $34.78 |
| Daily Range | $34.85 - $35.47 |
| 52-Week Range | $27.21 - $38.40 |
| Market Cap | $40.45B |
| P/E Ratio | 8.83 |
| Dividend (Yield) | 1.96 (5.60%) |
| Volume | 10,225,478 |
| Average Daily Volume | 0 |
LLY
VS S&P 500 (SPY)
How do you think LLY will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
LLY Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
LLY News and Commentary
- Bone Up On This Potential Blockbuster – The Motley Fool
- UPDATE: Eli Lilly CEO's 2009 Salary, Bonus Rose From '08 – SmartMoney
- Activists Increasingly Like Biotechs But With Mixed Results – SmartMoney
- Eli Lilly CEO's 2009 Salary, Bonus Rose From '08 – SmartMoney
- Sanofi Nears Decision On Combining Animal Unit With Merck's – SmartMoney
- Surfing the Wave of the Future: Personalized Medicine – The Motley Fool
- UPDATE: FDA Warns Sanofi, United Therapeutics On Promotional Material – SmartMoney
- UPDATE: FDA Warns Drug Companies On Promotional Material – SmartMoney
- FDA Warns Sanofi, United Therapeutics On Promotional Material – SmartMoney
- 5 Articles You've Got to Read – The Motley Fool
- A Trio of Foolish Tax Tips – The Motley Fool
- 2-Star Stocks Poised to Plunge: MannKind? – The Motley Fool
- The Tax Perk You Can't Afford to Miss – The Motley Fool
- Icahn Back to Batter Biogen – The Motley Fool
- All Grown Up, With Cash to Burn – The Motley Fool
- Health-Care Reform Is Dead. Probably. – The Motley Fool
- The Biggest Development-Stage Drugmaker, Ever – The Motley Fool
- Only the Strong Survive at Pfizer – The Motley Fool
- The Next Amgen? Not Yet. – The Motley Fool
- 2nd UPDATE: Bristol, Lilly 4Q Sales Up; Resolve Drug Dispute – SmartMoney
RSS Headlines
Fool UK
